Advertisement

Topics

Gritstone and bluebird Ink Deal to Target Tumors With Gene and Cell Therapies

20:00 EDT 22 Aug 2018 | BioSpace

Cambridge, Mass.-based bluebird bio and Gritstone Oncology inked a deal to combine gene and cell therapies to target cancer. This morning California-based Gritstone said it will leverage its artificial intelligence platform, dubbed EDGE, to analyze specific tumor types for the collaboration.

Original Article: Gritstone and bluebird Ink Deal to Target Tumors With Gene and Cell Therapies

NEXT ARTICLE

More From BioPortfolio on "Gritstone and bluebird Ink Deal to Target Tumors With Gene and Cell Therapies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...